Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer

详细信息    查看全文

• 作者：Bogdan Dascalu ; Hagen F. Kennecke ; Howard J. Lim…
• 关键词：EGFR inhibitor ; Prophylactic ; Reactive ; Colorectal cancer ; Acneiform ; Rash
• 刊名：Supportive Care in Cancer
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：24
• 期：2
• 页码：799-805
• 全文大小：261 KB
• 参考文献：1.Li T, Perez-Soler R (2009) Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 4:107PubMed CrossRef
  2.Jatoi A, Green EM, Rowland KM Jr et al (2009) Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology 77:120PubMed PubMedCentral CrossRef
  3.Jacot W, Bessis D, Jorda E et al (2004) Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 151:238PubMed CrossRef
  4.Busam KJ, Capodieci P, Motzer R et al (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144:1169PubMed CrossRef
  5.Wierzbicki R, Jonker DJ, Moore MJ et al (2011) A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining. Invest New Drugs 29:170CrossRef
  6.Jatoi A, Nguyen PL (2008) Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist 13:1201–1204PubMed CrossRef
  7.Wagner LL, Lacouture ME (2007) Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist’s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology 21(suppl 5):34–36PubMed
  8.Peréz-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23:5235–5246PubMed CrossRef
  9.Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and Cetuximab plus Irinotecan in Irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:341CrossRef
  10.Agero AL, Dusza SW, Benvenuto-Andrade C et al (2006) Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55:657PubMed CrossRef
  11.Perez-Soler R (2006) Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 8(suppl 1):S7PubMed CrossRef
  12.Kris M, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149–2158PubMed CrossRef
  13.Lacouture ME, Mitchell EP, Piperdi B et al (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28:1351–1352PubMed CrossRef
  14.Scope A, Agero AL, Dusza SW et al (2007) Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 25:5390PubMed CrossRef
  15.Jatoi A, Rowland K, Sloan JA et al (2008) Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 113:847PubMed PubMedCentral CrossRef
  16.Saltz L, Kjes MS, Abbruzzese J et al (2003) The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 22:204 (abstr 817)CrossRef
  17.Melosky B, Burkes R, Rayson D et al (2009) Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 16:16–26PubMed PubMedCentral CrossRef
  18.Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5:649–655PubMed CrossRef
  19.Peeters M, Siena S, Van Cutsem E et al (2009) Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving Panitumumab monotherapy. Cancer 115:1544PubMed CrossRef
  20.Van Cutsem E, Peeters M, Siena S et al (2007) Open-label, phase 3 clinical trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664PubMed CrossRef
  21.Saltz LB, Meropol NJ, Loehrer PJ Sr et al (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201–1208PubMed CrossRef
  22.Perez-Soler R, Chachoua A, Hammond LA et al (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238–3247PubMed CrossRef
  
• 作者单位：Bogdan Dascalu (1)
  Hagen F. Kennecke (1) (2)
  Howard J. Lim (1) (2)
  Daniel J. Renouf (1) (2)
  Jenny Y. Ruan (2)
  Jennifer T. Chang (2)
  Winson Y. Cheung (1) (2)
  
  1. Department of Medicine, University of British Columbia, 2775 Laurel Street, Vancouver, BC, V5Z 1M9, Canada
  2. Division of Medical Oncology, British Columbia Cancer Agency, Vancouver Clinic, 4415, 600 West 10th Avenue, 4th Floor, Vancouver, BC, V5Z 4E6, Canada
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Nursing
  Nursing Management and Research
  Pain Medicine
  Rehabilitation Medicine
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-7339

文摘

Purpose There are concerns regarding potential negative effects of prophylactic treatment of epidermal growth factor receptor (EGFR)-inhibitor-related rashes on metastatic colorectal cancer (mCRC) outcomes. We aimed to characterize treatment patterns of EGFR-inhibitor-induced rashes and evaluate prophylactic versus reactive approaches to rash management in relation to overall survival (OS).